GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mersana Therapeutics Inc (NAS:MRSN) » Definitions » Operating Margin %
中文

Mersana Therapeutics (Mersana Therapeutics) Operating Margin % : -195.57% (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Mersana Therapeutics Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Mersana Therapeutics's Operating Income for the three months ended in Dec. 2023 was $-20.93 Mil. Mersana Therapeutics's Revenue for the three months ended in Dec. 2023 was $10.70 Mil. Therefore, Mersana Therapeutics's Operating Margin % for the quarter that ended in Dec. 2023 was -195.57%.

Warning Sign:

Mersana Therapeutics Inc operating margin has been in a 5-year decline. The average rate of decline per year is -30.3%.

The historical rank and industry rank for Mersana Therapeutics's Operating Margin % or its related term are showing as below:

MRSN' s Operating Margin % Range Over the Past 10 Years
Min: -392693.02   Med: -463.86   Max: -54.91
Current: -463.86


MRSN's Operating Margin % is ranked worse than
63.65% of 1026 companies
in the Biotechnology industry
Industry Median: -177.195 vs MRSN: -463.86

Mersana Therapeutics's 5-Year Average Operating Margin % Growth Rate was -30.30% per year.

Mersana Therapeutics's Operating Income for the three months ended in Dec. 2023 was $-20.93 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-170.96 Mil.


Mersana Therapeutics Operating Margin % Historical Data

The historical data trend for Mersana Therapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mersana Therapeutics Operating Margin % Chart

Mersana Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial Premium Member Only -71.69 -10,641.30 -392,693.02 -766.59 -463.86

Mersana Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -312.00 -740.85 -530.33 -464.11 -195.57

Competitive Comparison of Mersana Therapeutics's Operating Margin %

For the Biotechnology subindustry, Mersana Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mersana Therapeutics's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mersana Therapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Mersana Therapeutics's Operating Margin % falls into.



Mersana Therapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Mersana Therapeutics's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-170.957 / 36.855
=-463.86 %

Mersana Therapeutics's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-20.928 / 10.701
=-195.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mersana Therapeutics  (NAS:MRSN) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Mersana Therapeutics Operating Margin % Related Terms

Thank you for viewing the detailed overview of Mersana Therapeutics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Mersana Therapeutics (Mersana Therapeutics) Business Description

Traded in Other Exchanges
Address
840 Memorial Drive, Cambridge, MA, USA, 02139
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
Executives
Anna Protopapas director, officer: President and CEO MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Mohan Bala officer: SVP, Chief Development Officer C/O MERSANA THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Tushar Misra officer: Chief Manufacturing Officer 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Brian Deschuytner officer: Sr. VP, Finance & Product stgy 840 MEMORIAL DRIVE, CAMBRIDGE MA 01776
Ashish Mandelia officer: VP, Controller 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Timothy B Lowinger officer: Chief Scientific Officer 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Alejandra Carvajal officer: Chief Legal Officer C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, 5TH FLOOR, CAMBRIDGE MA 02139
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Arvin Yang officer: Chief Medical Officer 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Hack Andrew A. F. director 300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
Michael J. Kaufman officer: Sr VP Chmistry, Man & Control 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Allene M. Diaz director C/O ALLENA PHARMACEUTIALS, INC., ONEW NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Eva M. Jack officer: CBO, Treasurer & Secretary 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Lawrence M Alleva director 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Scott D Sandell 10 percent owner

Mersana Therapeutics (Mersana Therapeutics) Headlines